| Bioactivity | DPTIP is a potent brain penetrant neutral sphingomyelinase 2 (N-SMase 2) inhibitor (exosome inhibitor), with an IC50 of 30 nM[1][2]. | |||||||||
| Invitro | DPTIP blocks EV secretion in a dose dependent manner (0.03-30 μM), and at 30 μM, this compound could decrease exosome release by 50% in astrocytes[2]. | |||||||||
| In Vivo | DPTIP potently (10 mg/kg IP) inhibits IL-1β-induced astrocyte-derived EV release[1]. Animal Model: | |||||||||
| Name | DPTIP | |||||||||
| CAS | 351353-48-5 | |||||||||
| Formula | C21H18N2O3S | |||||||||
| Molar Mass | 378.44 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Camilo Rojas, et al. DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation. Sci Rep. 2018 Dec 7;8(1):17715. [2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. |